Leigh Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Leigh Syndrome Market Outlook

Thelansis’s “Leigh Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Leigh Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Leigh Syndrome Overview

Leigh's syndrome, a rare inherited neurometabolic disorder affecting the central nervous system, typically emerges in infants aged three months to two years. However, it can infrequently arise during adolescence or early adulthood. Symptoms usually manifest before 12 months, but they may appear later in exceptional cases. Common initial symptoms include the loss of motor skills, hypotonia with poor head control, recurrent vomiting, and movement difficulties. Subsequently, pyramidal and extrapyramidal signs, nystagmus, breathing problems, ophthalmoplegia, and peripheral neuropathy may develop. Epilepsy is relatively uncommon. The syndrome causes problems with aerobic energy production, ranging from the pyruvate dehydrogenase complex to the oxidative phosphorylation pathway. Most mutations are in the nuclear genome, affecting genes related to the pyruvate dehydrogenase complex, respiratory complexes I or II, or proteins involved in respiratory complex IV assembly. Some individuals with Leigh syndrome carry mitochondrial DNA mutations, notably the 8993T>G or 8993T>C mutations in the MTATP6 gene. This subgroup, known as maternally inherited Leigh syndrome (MILS), has a high proportion of the mitochondrial DNA mutation. In contrast, a milder phenotype called NARP syndrome is associated with lower proportions of this mutation. In some cases, the genetic cause of Leigh syndrome remains unknown despite specific biochemical defects. Diagnosing the syndrome relies on brain imaging, which reveals characteristic brainstem and basal ganglia lesions, often with leucodystrophy and cerebral atrophy. Elevated lactate levels are consistently observed in cerebrospinal fluid and often in the blood. Biochemical investigations are used to identify the underlying energy production defect. Prenatal diagnosis is possible when a nuclear gene mutation is known, but it's more challenging when mitochondrial DNA is involved due to heteroplasmy. Currently, thiamine (Vitamin B1), oral sodium bicarbonate, or sodium citrate are commonly used treatments, although no specific approved treatment exists for Leigh's disease. The prognosis for Leigh's disease is generally poor. Individuals lacking mitochondrial complex IV activity and those with pyruvate dehydrogenase deficiency have the worst outlook, often succumbing within a few years. Those with partial deficiencies have a somewhat better prognosis, possibly surviving to 6 or 7 years of age and occasionally into their mid-teenage years.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: